-$1.74 EPS Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter

Brokerages expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to announce ($1.74) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.79) and the highest is ($1.67). Agios Pharmaceuticals reported earnings per share of ($1.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 6.7%. The business is scheduled to announce its next quarterly earnings results on Friday, May 3rd.

On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.73) per share for the current fiscal year, with EPS estimates ranging from ($7.41) to ($6.06). For the next year, analysts anticipate that the company will report earnings of ($6.32) per share, with EPS estimates ranging from ($7.25) to ($4.94). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.65) by $0.07. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $19.98 million. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business’s revenue for the quarter was up 200.0% on a year-over-year basis. During the same period last year, the firm posted ($1.81) earnings per share.

AGIO has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. ValuEngine lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Piper Jaffray Companies lowered their target price on Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 14th. Finally, Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Friday, February 15th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $97.86.

In other news, insider Scott Biller sold 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $65.00, for a total transaction of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares in the company, valued at $1,838,005. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Steven L. Hoerter sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $67.01, for a total value of $670,100.00. Following the sale, the insider now owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $1,896,700. Corporate insiders own 3.02% of the company’s stock.

A number of institutional investors have recently made changes to their positions in AGIO. Quantamental Technologies LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $28,000. Advisor Group Inc. lifted its position in shares of Agios Pharmaceuticals by 33.1% during the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 297 shares during the last quarter. ETF Managers Group LLC lifted its position in shares of Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 216 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 14.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 430 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $188,000. Institutional investors and hedge funds own 98.44% of the company’s stock.

Shares of Agios Pharmaceuticals stock traded up $2.00 during midday trading on Friday, reaching $67.44. The company had a trading volume of 612,967 shares, compared to its average volume of 416,000. The firm has a market cap of $3.82 billion, a P/E ratio of -11.18 and a beta of 2.38. Agios Pharmaceuticals has a fifty-two week low of $41.63 and a fifty-two week high of $99.82.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: What is the balance sheet?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.